Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement
Segments

Common Size IS
Op Efficiency
Credit Analysis

Tarsus Pharmaceuticals, Inc.

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-22Dec-31-21Dec-31-20Dec-31-19Dec-31-18
   8-K10-K10-K10-KS-1/A
Revenues:       
Total revenues       
Operating expenses:       
Research and development   41.718.83.2 
General and administrative  44.925.48.21.10.4
    Total operating expenses  177.1    
    Loss from operations before other income (expense) and income taxes  -63.5-12.2-27.0-4.3 
   
Other income (expense):       
Interest income  3.5    
Interest expense  -2.2    
Other (expense) income, net  0.1-0.1   
Change in fair value of equity warrants issued by licensee  -0.5    
    Total other income (expense), net  0.1-1.60.2-0.4 
Provision for income taxes  0.00.10.00.00.0
    Net (loss) income  -62.1-13.8-26.8-4.7 
   
Other comprehensive loss:       
    Comprehensive loss  -62.2-13.8-26.8-4.7 
   
Earnings Per Share [Abstract]       
Net loss per share, basic (usd per share)  ($2.52)($0.67)($4.32)($1.98)($0.75)
Net loss per share, diluted (usd per share)  ($2.52)($0.67)($4.32)($1.98)($0.75)
   
Weighted Average Number of Shares Outstanding, Diluted [Abstract]       
Weighted-average shares outstanding, basic (shares)  24.620.66.22.41,759.5
Weighted-average shares outstanding, diluted (shares)  24.620.66.2  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy